Human herpesvirus 6A nuclear matrix protein U37 interacts with heat shock transcription factor 1 and activates the heat shock response.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
28 09 2023
Historique:
medline: 4 10 2023
pubmed: 6 9 2023
entrez: 6 9 2023
Statut: ppublish

Résumé

Nascent nucleocapsids of herpesviruses acquire a primary envelope during their nuclear export by budding through the inner nuclear membrane into the perinuclear space between the inner and outer nuclear membranes. This process is mediated by a conserved viral heterodimeric complex designated the nuclear egress complex, which consists of the nuclear matrix protein and the nuclear membrane protein. In addition to its essential roles during nuclear egress, the nuclear matrix protein has been shown to interact with intracellular signaling pathway molecules including NF-κB and IFN-β to affect viral or cellular gene expression. The human herpesvirus 6A (HHV-6A) U37 gene encodes a nuclear matrix protein, the role of which has not been analyzed. Here, we show that HHV-6A U37 activates the heat shock element promoter and induces the accumulation of the molecular chaperone Hsp90. Mechanistically, HHV-6A U37 interacts with heat shock transcription factor 1 (HSF1) and induces its phosphorylation at Ser-326. We report that pharmacological inhibition of HSF1, Hsp70, or Hsp90 decreases viral protein accumulation and viral replication. Taken together, our results lead us to propose a model in which HHV-6A U37 activates the heat shock response to support viral gene expression and replication. IMPORTANCE Human herpesvirus 6A (HHV-6A) is a dsDNA virus belonging to the

Identifiants

pubmed: 37671864
doi: 10.1128/jvi.00718-23
pmc: PMC10537701
doi:

Substances chimiques

Heat Shock Transcription Factors 0
Viral Matrix Proteins 0
HSF1 protein, human 0
HSP90 Heat-Shock Proteins 0
HSP70 Heat-Shock Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0071823

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

EMBO J. 1998 Feb 16;17(4):1087-95
pubmed: 9463386
Antivir Chem Chemother. 2005;16(2):135-46
pubmed: 15889536
J Virol. 2005 Oct;79(20):13037-46
pubmed: 16189006
J Virol. 2013 Sep;87(18):10126-38
pubmed: 23843639
FASEB J. 2001 May;15(7):1118-31
pubmed: 11344080
Sci Rep. 2020 Nov 2;10(1):18877
pubmed: 33139753
Nature. 2010 Oct 14;467(7317):859-62
pubmed: 20944748
J Virol. 2004 Jul;78(13):7175-85
pubmed: 15194794
J Virol. 2011 May;85(10):4947-53
pubmed: 21389131
PLoS Pathog. 2015 Jun 17;11(6):e1004957
pubmed: 26083367
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14276-81
pubmed: 21821792
J Virol. 2003 Feb;77(4):2452-8
pubmed: 12551983
Cancer Chemother Pharmacol. 2010 Aug;66(3):535-45
pubmed: 20012863
Front Microbiol. 2022 Jan 10;12:799890
pubmed: 35082770
J Virol. 2014 Jan;88(1):249-62
pubmed: 24155370
Biotechniques. 2006 Feb;40(2):191-7
pubmed: 16526409
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12396-401
pubmed: 14519856
Mol Cell Biol. 1998 Sep;18(9):4949-60
pubmed: 9710578
J Biochem. 2018 Dec 1;164(6):397-406
pubmed: 30107464
J Virol. 2022 Oct 12;96(19):e0126422
pubmed: 36154610
J Gen Virol. 2013 Sep;94(Pt 9):2056-2069
pubmed: 23740483
Nat Commun. 2014 Jun 11;5:4131
pubmed: 24916797
J Infect Dis. 1990 Oct;162(4):852-7
pubmed: 2169499
J Virol. 2005 Aug;79(16):10740-9
pubmed: 16051866
Sci Rep. 2017 May 15;7(1):1882
pubmed: 28507315
J Virol. 2017 May 26;91(12):
pubmed: 28356536
J Virol. 2022 Jan 26;96(2):e0170421
pubmed: 34730397
J Virol. 2014 Apr;88(7):3815-25
pubmed: 24453362
J Virol. 2019 Jun 28;93(14):
pubmed: 31043535
PLoS Pathog. 2022 Jul 8;18(7):e1010623
pubmed: 35802751
Clin Cancer Res. 2002 May;8(5):986-93
pubmed: 12006510
Nat Commun. 2018 Aug 23;9(1):3379
pubmed: 30139939
J Biol Chem. 2011 Jan 21;286(3):1737-47
pubmed: 21078672
Virology. 2010 Nov 25;407(2):360-7
pubmed: 20863544
Mol Cell Biol. 2003 Sep;23(17):6013-26
pubmed: 12917326
PLoS Pathog. 2012;8(10):e1002951
pubmed: 23055929
Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):9010-5
pubmed: 26150520
Nat Biotechnol. 1998 Sep;16(9):833-8
pubmed: 9743115
Cell. 2015 Dec 17;163(7):1692-701
pubmed: 26687357
J Virol. 2019 Oct 15;93(21):
pubmed: 31391274
Nat Rev Mol Cell Biol. 2010 Aug;11(8):545-55
pubmed: 20628411
Cell. 1998 Aug 21;94(4):471-80
pubmed: 9727490
PLoS One. 2014 Jun 05;9(6):e99425
pubmed: 24901434
J Biol Chem. 2020 Mar 6;295(10):3189-3201
pubmed: 31980459
J Virol. 2016 Sep 29;90(20):8994-9007
pubmed: 27466427
J Clin Microbiol. 1991 Feb;29(2):367-72
pubmed: 1848868
PLoS Pathog. 2012 Sep;8(9):e1002904
pubmed: 22969426
EMBO J. 2015 Dec 2;34(23):2921-36
pubmed: 26511020
J Biol Chem. 2015 Nov 13;290(46):27452-8
pubmed: 26432641
J Virol. 2017 Oct 27;91(22):
pubmed: 28878082
Arch Virol. 2014 May;159(5):863-70
pubmed: 24193951
Glia. 2006 Jun;53(8):789-98
pubmed: 16541415
Viruses. 2021 Apr 25;13(5):
pubmed: 33923040
J Clin Virol. 2006 Dec;37 Suppl 1:S24-6
pubmed: 17276363
J Virol. 1990 May;64(5):2033-40
pubmed: 2157870
J Virol. 2021 Nov 9;95(23):e0126921
pubmed: 34549982
Front Microbiol. 2022 Feb 03;12:797279
pubmed: 35185822
Cells. 2022 Jun 04;11(11):
pubmed: 35681532
J Virol. 2001 Sep;75(18):8803-17
pubmed: 11507225
Virology. 2016 Oct;497:279-293
pubmed: 27498410
Nat Rev Microbiol. 2011 May;9(5):382-94
pubmed: 21494278
Cell Rep. 2015 Dec 29;13(12):2645-52
pubmed: 26711332
EMBO J. 2015 Dec 2;34(23):2937-52
pubmed: 26511021
Cell Stress Chaperones. 2000 Nov;5(5):471-80
pubmed: 11189454
J Gen Virol. 1993 Dec;74 ( Pt 12):2691-8
pubmed: 8277274
J Gen Virol. 2008 Mar;89(Pt 3):731-740
pubmed: 18272765
J Gen Virol. 1993 Oct;74 ( Pt 10):2257-62
pubmed: 8409948
Microbiol Spectr. 2022 Feb 23;10(1):e0188321
pubmed: 35196784
J Biol Chem. 2022 Mar;298(3):101625
pubmed: 35074430
J Gen Virol. 1999 Jan;80 ( Pt 1):63-68
pubmed: 9934685
Clin Chim Acta. 2019 Nov;498:90-100
pubmed: 31437446
Viruses. 2022 Feb 26;14(3):
pubmed: 35336886

Auteurs

Jing Rin Huang (JR)

Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine , Kobe, Hyogo, Japan.

Jun Arii (J)

Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine , Kobe, Hyogo, Japan.

Mansaku Hirai (M)

Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine , Kobe, Hyogo, Japan.

Mitsuhiro Nishimura (M)

Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine , Kobe, Hyogo, Japan.

Yasuko Mori (Y)

Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine , Kobe, Hyogo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH